GLANDGland Pharma Ltd.

    Gland Pharma gives Euro 20 Mn guarantee for Phixen SAS facility

    • Agreement
    • pharmaceuticals
    A dark wooden apothecary cabinet with small drawers and shelves holding white and blue glass medicine bottles, in a museum display.
    先従隗始, via Wikimedia Commons (CC0). Illustrative image.

    Gland Pharma (NSE: GLAND) has issued a corporate guarantee of Euro 20 Mn in favour of MUFG Bank (Europe) N.V. for its wholly owned step-down subsidiary Phixen SAS, it said in a filing on 12 Nov 2026. The guarantee secures draw-downs under an uncommitted Euro 50 Mn revolving facility.

    What the guarantee covers

    Gland Pharma has extended a corporate guarantee of Euro 20 Mn in favour of MUFG Bank to secure the draw-down amount and interest on a facility taken by Phixen SAS. The facility is an uncommitted revolving facility of Euro 50 Mn, with an initial draw-down limit of Euro 18 Mn, and the guarantee is set against that initial limit.

    If Phixen SAS fails to repay MUFG Bank, the company has to repay the draw-down amount along with interest. The guarantee will be treated as a contingent liability for the company. The facility agreement is valid for three years, and the guarantee is valid until 31 Mar 2030.

    How the limit could change

    The company says it may extend the limit of the guarantee in favour of MUFG Bank if draw-down limits to Phixen SAS increase in the future, and that any such change will be informed to the stock exchanges.

    Phixen SAS is a wholly owned step-down subsidiary of Gland Pharma. For scale, the company's Q2 FY27 consolidated total income was ₹1,902.64 crore and net profit was ₹290.76 crore. The guarantee is stated only in euros, so its size in rupees is not given in the filing.

    What the guarantee means for Gland Pharma's shareholders

    Not stated: the reason the guarantee was issued for Phixen SAS, the date it was given, and how much of the draw-down is outstanding. The next dated step is the expiry of the guarantee on 31 Mar 2030.

    At a glance

    ItemDetail
    GuarantorGland Pharma Limited
    Beneficiary of facilityPhixen SAS, wholly owned step-down subsidiary
    LenderMUFG Bank (Europe) N.V.
    FacilityUncommitted Revolving Facility Agreement, Euro 50 Mn
    Initial draw-down limitEuro 18 Mn
    Guarantee amountEuro 20 Mn
    Facility validity3 years
    Guarantee valid till31 Mar 2030

    Filed with NSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Related posts

    All Gland Pharma Ltd. articles